Neuro-Oncology News

PHILADELPHIA — Fox Chase Cancer Center today hosted a Regional Cancer Moonshot Summit in conjunction with the National Cancer Moonshot Summit held in Washington, D.C., marking the first time that stakeholders representing all cancer types convened under one national charge.

Nancy E. Davidson, MD, director of University of Pittsburgh Cancer Institute, took over as president of the American Association for Cancer Research this spring.

Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation, has been named acting director of the agency’s new Oncology Center of Excellence.

Lifestyle choices can contribute considerably to a person’s cancer risk, as well the outcomes they achieve after they are diagnosed with a malignancy.

James P. Allison, PhD, chair of the department of immunology and executive director of the immunotherapy platform at MD Anderson Cancer Center in Houston, discusses toxicities related to immune-based strategies to treat cancer.

CHICAGO — Candace Johnson, PhD, president and CEO of Roswell Park Cancer Institute, discusses how research in immunotherapy and genomics can lead to tailored personalized treatments at the ASCO Annual Meeting.

CHICAGO — Dawn L. Hershman, MD, MS, associate professor of medicine at Columbia University Medical Center, reviews study results that identified comorbidities and lifestyle-related factors that can predict chemotherapy-induced peripheral neuropathy risk at the ASCO Annual Meeting.

Employees of SLACK Incorporated — publisher of HemOnc Today — wore white today in support of White Out Cancer Day.

Combined chemotherapy and radiation significantly improved OS over radiation alone in patients with glioblastoma multiforme who underwent biopsy alone, according to study results published in Cancer.

Gross total resection appeared to improve OS and PFS compared with subtotal resection in adults with glioblastoma multiforme, according to the results of a retrospective meta-analysis.